Sign In
Buy CMPS
$12.69
-0.640 (-4.80%)
At Close: Jun 03, 2026
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
06:30am, Tuesday, 05'th Aug 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass (CMPS) Q2 Loss Improves 27%
01:16am, Friday, 01'st Aug 2025
Compass (CMPS) Q2 Loss Improves 27%
COMPASS Pathways plc (CMPS) Q2 2025 Earnings Call Transcript
10:32am, Thursday, 31'st Jul 2025
COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2025 Earnings Call July 31, 2025 8:00 PM ET Company Participants Guy Goodwin - Chief Medical Officer Kabir Kumar Nath - CEO & Director Lori Englebert - Chief Com
Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
06:30am, Thursday, 31'st Jul 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways Appoints Justin Gover to Board of Directors
06:30am, Tuesday, 29'th Jul 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025
06:30am, Tuesday, 22'nd Jul 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
04:48am, Sunday, 20'th Jul 2025
Investors seeking stocks that can put up dramatic gains in a short amount of time can find what they're looking for in the biotechnology industry. Investment bank analysts on Wall Street have tagged a
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
04:00pm, Thursday, 10'th Jul 2025
NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, annou
COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 08'th Jul 2025
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360
02:47pm, Tuesday, 24'th Jun 2025
I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 d
Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint
12:30pm, Monday, 23'rd Jun 2025
Compass Pathways (NASDAQ:CMPS) has reported positive results from its Phase 3 trial of its synthetic formulation of psilocybin, COMP360, in patients with treatment-resistant depression (TRD), with the
Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:25am, Monday, 23'rd Jun 2025
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.
Compass Pathways stock slip as psilocybin depression trial falls short of expectations
08:12am, Monday, 23'rd Jun 2025
Shares of Compass Pathways Plc plunged as much as 37% during pre-market trading on Monday after the company's experimental psilocybin treatment for a form of hard-to-treat depression produced results
Compass Pathways' depression drug succeeds late-stage trial
06:48am, Monday, 23'rd Jun 2025
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod
